While there has been tremendous progress in treating cancer over the last 25 years, there is still much we do not understand about the disease. The fact that cancer is the second-leading cause of death in the U.S., annually leading to the deaths of more than 590,000 Americans, is proof that the field needs new ideas and new approaches. By using state-of-the-art genomic technologies and an unprecedented level of collaboration with the leading research institutions in New York, the NYGC is on the cutting edge of investigation into the origins, diagnosis and evolution of cancer.
Genome Center Cancer Group and Polyethnic-1000 Project
The NYGC seeks to build on our strengths in the field of cancer research and genomics. To accomplish this, we plan to use our Genome Center Cancer Group (GCCG), which brings together the top leaders in cancer research, led by Harold Varmus, MD, NYGC and Weill Cornell Medicine, and Charles Sawyers, MD, Memorial Sloan Kettering Cancer Center, to advance collaborative efforts in cancer genomics and our Polyethnic-1000 Project, organized by the GCCG, to accelerate cancer genomics research by focusing on whole genome sequencing of individuals with cancer and their tumors, novel population-level cancer analytics, and the application of both single cell and spatial transcriptomics.
Computational Cancer Genomics Working Group
The GCCG and Polyethnic-1000 initiatives serve as models for our new Computational Cancer Genomics Working Group led by Simon Tavaré, PhD, NYGC and Columbia University, and Sohrab Shah, PhD of Memorial Sloan Kettering Cancer Center. This group will build collaborations that apply novel statistical approaches and population-level analyses to major cohorts in cancer genomics.
NYGC Core Faculty Members Marcin Imielinski, MD, PhD; Dan Landau, MD, PhD; and Neville Sanjana, PhD, are all also engaged in pioneering cancer research.